Psychedelic Alpha Partners with Horizons to Present The Psychedelic Business Forum

NEW YORK – The Psychedelic Business Forum, Horizons: Perspectives on Psychedelics, returns to the New York Academy of Medicine on October 15, 2026, with Psychedelic Alpha formalized this year as a co-presenter alongside Horizons.

Horizons confirmed the arrangement on its website, describing the day as “a collaboration between Horizons and Psychedelic Alpha, an independent media and consultancy firm.” The language marks a step beyond their earlier working relationship. Psychedelic Alpha served as a media sponsor for the event in 2022, and founder Josh Hardman opened that year’s Business Forum. This time, the partnership is structural. Psychedelic Alpha has a direct role in shaping the program.

The backdrop matters. On April 18, 2026, the White House established psychedelic medicine as a national priority, and within days, the FDA committed to an accelerated review of three specific psychedelic therapy candidates. Those developments injected fresh urgency into a sector that had spent several years recalibrating after a capital downturn and a string of late-stage trial setbacks.

The forum’s agenda covers six substantive areas:

• A state-of-industry briefing.
• Federal regulatory strategy.
• Capital formation for drug development.
• Insurance reimbursement timelines.
• A commercialization session focused on post-approval infrastructure.
• Clinical preparedness for practitioners and operators.

That last category, clinic readiness and workforce capacity, has historically received less airtime at industry gatherings, and its presence here highlights that the organizers see commercial urgency in treating it as a front-burner issue.

Psychedelic Alpha describes its mission as bringing “clarity, rigor, and context” to the psychedelics field, providing data-driven insights into drug development, regulation, and commercialization. As a media and consultancy operation rather than a trade publication or advocacy platform, the firm brings a different sensibility to the co-presenter role – one rooted in deal-flow monitoring and clinical-pipeline tracking rather than sector boosterism.

Horizons, now entering its 19th year, was founded in 2007 by Kevin Balktick as a single-day event and has since grown into the longest-running annual psychedelic conference in the world. The Business Forum was introduced in 2021 as an expanded addition to the main program and has grown in scope and attendance each year since.

The forum runs on Thursday, October 15, followed by Science, Medicine, and Psychedelics on October 16 and Psychedelics in the World on October 17. All sessions are held at the New York Academy of Medicine at 1216 Fifth Avenue. Registration is open now at horizonsconference.org.

The addition of Psychedelic Alpha as a structural co-presenter adds something the Business Forum has long needed, a rigorous data layer under the commercial conversation. With FDA approvals now a near-term probability rather than a projection, the questions on reimbursement, clinic infrastructure, and capital formation are no longer strategic planning exercises. They need concrete answers, and this program is organized to try to provide them.